## Coverage Summary

### Allergy Testing and Allergy Immunotherapy

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved by:</td>
<td>UnitedHealthcare Medicare Benefit Interpretation Committee</td>
<td>Last Review Date: 03/19/2019</td>
</tr>
</tbody>
</table>

**Related Medicare Advantage Policy Guidelines:**

- Antigens Prepared for Sublingual Administration (NCD 110.9)
- Challenge Ingestion Food Testing (NCD 110.12)
- Cytotoxic Food Tests (NCD 110.13)
- Food Allergy Testing and Treatment (NCD 110.11)
- Intravenous Histamine Therapy (NCD 30.6)

---

This information is being distributed to you for personal reference. The information belongs to UnitedHealthcare and unauthorized copying, use, and distribution are prohibited. This information is intended to serve only as a general reference resource and is not intended to address every aspect of a clinical situation. Physicians and patients should not rely on this information in making health care decisions. Physicians and patients must exercise their independent clinical discretion and judgment in determining care. Each benefit plan contains its own specific provisions for coverage, limitations, and exclusions as stated in the Member’s Evidence of Coverage (EOC)/Summary of Benefits (SB). If there is a discrepancy between this policy and the member’s EOC/SB, the member’s EOC/SB provision will govern. The information contained in this document is believed to be current as of the date noted.

The benefit information in this Coverage Summary is based on existing national coverage policy, however, Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable.

There are instances where this document may direct readers to a UnitedHealthcare Commercial Medical Policy, Medical Benefit Drug Policy, and/or Coverage Determination Guideline (CDG). In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

---

### INDEX TO COVERAGE SUMMARY

<table>
<thead>
<tr>
<th>I. COVERAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Allergy Testing</td>
</tr>
<tr>
<td>2. Allergen Immunotherapy</td>
</tr>
<tr>
<td>3. Examples of Allergy Tests/Services</td>
</tr>
</tbody>
</table>

| II. DEFINITIONS |
| III. REFERENCES |
| IV. REVISION HISTORY |
| V. ATTACHMENTS |

### I. COVERAGE

**Coverage Statement:** Allergy testing and allergy immunotherapy (allergy therapy) are covered when Medicare coverage criteria are met.

**Guidelines/Notes:**

1. **Allergy Testing**

   Allergy testing may be covered when Medicare coverage criteria are met.

   *See the *Medicare Claims Processing Manual, Chapter 12, §200 - Allergy Testing and Immunotherapy.* (Accessed December 20, 2018)*

   *Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist and compliance*
2. **Allergen Immunotherapy**

Payment may be made for a reasonable supply of antigens that have been prepared for a particular patient if:

- the antigens are prepared by a physician who is a doctor of medicine or osteopathy, and
- the physician who prepared the antigens has examined the patient and has determined a plan of treatment and a dosage regimen.

Antigens must be administered in accordance with the plan of treatment and by a doctor of medicine or osteopathy or by a properly instructed person (who could be the patient) under the supervision of the doctor. The associations of allergists that CMS consulted advised that a reasonable supply of antigens is considered to be not more than a 12-month supply of antigens that has been prepared for a particular patient at any one time. The purpose of the reasonable supply limitation is to assure that the antigens retain their potency and effectiveness over the period in which they are to be administered to the patient. (See §20.2 and §50.2.)

- Also see the Medicare Claims Processing Manual, Chapter 12, §200 - Allergy Testing and Immunotherapy. (Accessed December 20, 2018)
- Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist and compliance with these policies is required where applicable. These LCDs/LCAs are available at https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx. (Accessed December 20, 2018)

3. **Examples of allergy tests/services include but are not limited to:**

   a. Sublingual antigen; see the NCD for Antigens for Sublingual Administration (110.9). (Accessed December 20, 2018)

   b. Intravenous histamine administration; see the NCD for Intravenous Histamines (30.6). (Accessed December 20, 2018)

   c. Routine radioallergosorbent test (RAST)

      - Medicare does not have a National Coverage Determination (NCD) for RAST.
      - Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist and compliance with these policies is required where applicable. For state-specific LCDs/LCAs, refer to the LCD Availability Grid (Attachment A).

      - For states with no LCDs/LCAs, refer to the MCG™ Care Guidelines, 23rd edition, 2019, Quantitative Allergen-Specific IgE Antibody Assays ACG: A-0149 (AC) for coverage guideline. (IMPORTANT NOTE: After checking the LCD Availability Grid and searching the Medicare Coverage Database, if no state LCD/LCA is found, then use the above referenced policy.)

      - Committee approval date: March 19, 2019
      - Accessed October 1, 2019

   d. Cytotoxicity testing/Bryan’s test; see the NCD for Cytotoxic Food Tests (110.13). (Accessed December 20, 2018)

   e. Provocative and neutralizing testing (subcutaneous) for food allergies; see the NCD for
II. DEFINITIONS

III. REFERENCES

See above

IV. REVISION HISTORY

04/01/2019  Updated policy introduction; added language to clarify:
- There are instances where [the Coverage Summary] may direct readers to a UnitedHealthcare Commercial Medical Policy, Medical Benefit Drug Policy, and/or Coverage Determination Guideline (CDG)
- In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (*Medicare IOM Pub. No. 100-16, Ch. 4, §90.5*)

03/19/2019  Re-review with the following update:
Guideline 1.h [Radioallergosorbent Test (RAST) (CPT code 86003 and 86008)] - Updated the MCG™ reference from 22nd edition 2018 to the 23rd edition 2019; no change in MCG™ guideline; no change in the Coverage Summary guideline.

01/15/2019  Annual review with the following updates:
Guideline 1.a – 1.f
- Deleted the following examples (not addressed in the reference Medicare manual):
  a. Complete blood count (CBC) with differential (e.g., eosinophil count, IgE level, smear of nasal secretions)
  b. Chest X-ray, when respiratory symptoms are present
  c. Skin testing
  d. Total gamma globulins
  e. Sputum exam
  f. Paranasal sinus X-ray
- Updated the statement that LCDs are available to a general statement deleting specific LCD titles.
Guideline 1.g (Challenge ingestion food testing) - moved to the new Guideline 3 (Examples of allergy test/services)
Guideline 1.h [Radioallergosorbent Test (RAST) (CPT code 86003 and 86008)] - moved to the new Guideline 3 (Examples of allergy test/services)
Guideline 2 (Allergen Immunotherapy)
- Delete the following (duplicate language in Guideline 3):
  *Allergen immunotherapy to treat allergies is covered when:*
a. Patient is examined by a physician.
b. The physician who examines the patient, prepares the antigens and develops a plan of care and dosage regimen.

- Delete the following (Medicare reference not found):
  Note: Physician should instruct member on self-administration if member is capable of doing the injections. If a member lives too far from the allergist (rural area) the allergist may prepare the antigens and send the reasonable supply to another physician or qualified healthcare professional for administration.

- Deleted the following duplicate Medicare references:
  See the Medicare Benefit Policy Manual, Chapter 15, §50.4.4.1 - Antigens
  Also see the Medicare Claims Processing Manual, Chapter 12, §200 - Allergy Testing and Immunotherapy

Local Coverage Determinations (LCDs) exist and compliance with these policies is required where applicable. See these LCDs for (1) Allergen Immunotherapy, (2) Allergen Skin Testing, (3) Allergy Testing, and (4) Rast Type Tests are available at https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx.

Guideline 3 - Deleted “3. Reasonable Supply of Antigen”, making the rest of the guideline as part of Guideline 2.

Guideline 4 - changed to Guideline 3 (Examples of allergy test/services); updated language to read: Examples of allergy tests/services include but are not limited to:

Guideline 4.f - deleted “Urine auto injection; see the Wisconsin Physicians LCD for Allergy Immunotherapy (L36408)” (No NCD; current reference is an LCD)

Guideline 4.g - deleted “Skin titration/Rinkel method; see the Wisconsin Physicians LCD for Allergy Testing (L36402)” (No NCD; current reference is an LCD)

Guideline 4.i - deleted “Serum allergy/histamine release tests; see the Wisconsin Physicians LCD for Allergy Testing (L36402)” (No NCD; current reference is an LCD)

03/20/2018 Re-review with the following update:

Guideline 1.h [Radioallergosorbent Test (RAST) (CPT code 86003 and 86008)]
- Updated the MCG™ reference from 21st edition 2017 to the 22nd edition 2018;
- Added CPT code 86008 to guideline title.

01/16/2018 Annual review with the following updates:

Guideline 4.e (Urine auto injection) - Added CMS reference.
Guideline 4.f (Skin titration/Rinkel method) - Added CMS reference.
Guideline 4.i (Serum allergy/histamine release tests) - Added CMS reference.

03/21/2017 Re-review with the following update:


01/17/2017 Annual review; no updates.

09/20/2016 Re-review with the following updates:
• Guideline 1.h [Radioallergosorbent Test (RAST) (CPT code 86003)] -
  o For states with no LCDs replaced current default from the Wisconsin LCD for
    Allergy Testing and Allergy Immunotherapy (L34597) (retired) with the
    MCG™ Care Guidelines, 20th edition, 2016, Quantitative Allergen-Specific
    IgE Antibody Assays ACG: A-0149 (AC).
  o Moved the following language:
    “See the Medicare Claims Processing Manual, Chapter 12, § 200 Allergy
    Testing and Immunotherapy at

Local Coverage Determinations (LCDs) exist and compliance with these
policies is required where applicable. See LCDs for (1) Allergen
Immunotherapy, (2) Allergen Skin Testing, (3) Allergy Testing, and (4) Allergy
Testing and Allergy Immunotherapy (5) Rast Type Tests Allergy Tests and (6)
at https://www.cms.gov/medicare-coverage-database/overview-and-quick-
search.aspx.” to below Guideline 1.f.

• Guideline 2. Note section - Removed reference to the retired LCDs for Allergy
  Testing and Allergy.

• Guideline 3 (Reasonable Supply of Antigen) - Added the following verbiage
  explaining the definition Reasonable Supply of Antigen and appropriate reference
  link to the Medicare Benefit Policy Manual, Chapter 15, §50.4.4.1 Antigens:

  “Reasonable Supply of Antigen

  Payment may be made for a reasonable supply of antigens that have been
  prepared for a particular patient if: (1) the antigens are prepared by a physician
  who is a doctor of medicine or osteopathy, and (2) the physician who prepared the
  antigens has examined the patient and has determined a plan of treatment and a
  dosage regimen.

  Antigens must be administered in accordance with the plan of treatment and by a
  doctor of medicine or osteopathy or by a properly instructed person (who could be
  the patient) under the supervision of the doctor. The associations of allergists that
  CMS consulted advised that a reasonable supply of antigens is considered to be
  not more than a 12-month supply of antigens that has been prepared for a
  particular patient at any one time. The purpose of the reasonable supply limitation
  is to assure that the antigens retain their potency and effectiveness over the period
  in which they are to be administered to the patient. (See §§20.2 and 50.2.)”

• Definitions:
  Reasonable Supply of Antigen -Moved to section Guideline 3.

01/19/2016 Annual review with the following changes: Updated reference link(s) of the applicable
  LCDs to reflect the new condensed LCD link(s).

03/12/2015 Formatting change only.

02/15/2015 Annual review with following updates:

  • Updated Guidelines #1.h Radioallergosorbent Test (RAST):
    o Removed coverage summary guideline; added reference link to the default
      Wisconsin LCD for Allergy testing and allergy immunotherapy (L30471).
    o Added language to indicate:
UHC MA Coverage Summary: Allergy Testing and Allergy Immunotherapy

Proprietary Information of UnitedHealthcare. Copyright 2019 United HealthCare Services, Inc.

Coverage guidelines of the available LCD align; there is uniformity. There is no applicable UnitedHealthcare Policy available at this time

- Definitions:
  - Dose- deleted, unable find CMS reference.
  - Reasonable supply of antigen - Updated definition and added applicable CMS reference.

02/18/2014  Annual review; no updates.
02/19/2013  Annual review; no updates.
02/27/2012  Annual review; no updates.
08/23/2011  Updated the LCD Availability Grid (Attachment A); deleted retired LCDs, Trailblazer L17419 and Palmetto L5625, L6955, L67882 and L17429.
02/21/2011  Annual review; Updated Guidelines #1.h - Radioallergosorbent Test (RAST) using the standard Coverage Summary language format and using L30471 guidelines for states with no LCDs.

V. ATTACHMENT(S)

<table>
<thead>
<tr>
<th>LCD ID</th>
<th>LCD Title</th>
<th>Contractor Type</th>
<th>Contractor</th>
<th>States</th>
</tr>
</thead>
<tbody>
<tr>
<td>L33261</td>
<td>Allergy Testing</td>
<td>A and B MAC</td>
<td>First Coast Service Options, Inc.</td>
<td>FL, PR, VI</td>
</tr>
<tr>
<td>L36241</td>
<td>Allergy Testing</td>
<td>A and B MAC</td>
<td>Novitas Solutions, Inc.</td>
<td>AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX</td>
</tr>
<tr>
<td>L36402</td>
<td>Allergy Testing</td>
<td>MAC - Part A &amp; B</td>
<td>Wisconsin Physicians Service Insurance Corporation</td>
<td>IA, IN, KS, MI, MO, NE</td>
</tr>
<tr>
<td>L34313</td>
<td>Allergy Testing</td>
<td>A and B MAC</td>
<td>Noridian Healthcare Solutions</td>
<td>CA-NORTHERN, CA-SOUTHERN, AS, GU, HI, MP, NV</td>
</tr>
<tr>
<td>L33591</td>
<td>RAST Type Tests</td>
<td>A and B MAC</td>
<td>National Government Services, Inc.</td>
<td>CT, IL, MA, ME, MN, NH, NY, RI, VT, WI</td>
</tr>
<tr>
<td>L34063</td>
<td>RAST Type Tests</td>
<td>MAC - Part A &amp; B</td>
<td>CGS Administrators, LLC</td>
<td>KY, OH</td>
</tr>
</tbody>
</table>

End of Attachment A